PetVivo (PETV) 10-Q 24 Aug 18 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Jun. 30, 2018shares
Document And Entity Information
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	1,512,922
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	20,183,209
Trading Symbol	PETV
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Current Assets
Cash and cash equivalents	$ 32,326	$ 237,335
Accounts receivable		163
Inventory	104,284	25,554
Employee Advance	2,500	2,500
Security Deposit	8,201	10,200
Prepaids	26,495	19,948
Total Current Assets	173,806	295,700
Property and Equipment:
Property & equipment	145,863	122,682
Less: accumulated depreciation	(105,763)	(104,111)
Total Fixed Assets	40,100	18,571
Other Assets:
Trademark and patents-net	1,126,654	1,253,510
Total Other Assets	1,126,654	1,253,510
Total Assets	1,340,560	1,567,781
Current Liabilities
Accounts payable & accrued expenses	718,195	767,970
Note payable and accrued interest-related party	102,776	103,279
Accrued expenses - related party	595,066	559,884
Total Current Liabilities	1,386,037	1,431,133
Commitments and Contingencies
Stockholders' Equity:
Preferred stock, par value $0.001, 20,000,000 shares authorized, issued 0 and 0 shares outstanding at June 30, 2018 and March 31, 2018	0	0
Common stock, par value $0.001, 250,000,000 shares authorized, issued 20,183,209 and 18,279,075 shares outstanding at June 30, 2018 and March 31, 2018	20,183	18,279
Common stock to be issued	96,592	608,966
Additional Paid-In Capital	49,685,487	47,257,557
Accumulated Deficit	(49,847,739)	(47,748,154)
Total Stockholders' Equity	(45,477)	136,648
Total Liabilities and Stockholders' Equity	$ 1,340,560	$ 1,567,781

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2018	Mar. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	20,183,209	18,279,075
Common stock, shares outstanding	20,183,209	18,279,075

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenues		$ 1,183
Cost of Sales
Gross Profit		1,183
Operating Expenses:
Research and Development		23,866
General and Administration	2,097,088	460,638
Total Operating Expenses	2,097,088	484,504
Operating Loss	(2,097,088)	(483,321)
Other Income (Expense)
Gain on Settlement of Debt
Interest Expense	(2,497)	(17,710)
Total Other Income (Expense)	(2,497)	(17,710)
Net Loss before taxes	(2,099,585)	(501,031)
Income Tax Provision
Net Loss	$ (2,099,585)	$ (501,031)
Net Income (Loss) Per Share- Basic And Diluted	$ (0.11)	$ (0.03)
Weighted Average Common Shares Outstanding-Basic And Diluted	19,584,396	14,984,193

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]	Stock to be Issued [Member]	Total
Balance at Mar. 31, 2017	$ 9,322	$ 30,567,761	$ (45,410,816)	$ 14,303,559	$ 1,349,919	$ 819,745
Balance, shares at Mar. 31, 2017	9,321,306
Common stock issued to reduce accrued salaries	$ 2,100	1,207,819			(1,209,919)
Common stock issued to reduce accrued salaries, shares	2,100,128
Common stock returned - salary settlement	$ (682)	(342,045)				(342,727)
Common stock returned - salary settlement, shares	(681,600)
Common stock returned - escrow agreement	$ (1,250)					(1,250)
Common stock returned - escrow agreement, shares	(1,250,000)
Common stock issued to reduce debt	$ 38	13,172			(13,210)
Common stock issued to reduce debt, shares	37,741
Proceeds from stock sale					877,000	877,000
Stock based compensation granted	$ 1,250	670,796			191,825	863,871
Stock based compensation granted, shares	1,250,000
Stock granted for debt conversion					195,176	195,176
Common stock issued for cash	$ 1,620	565,380			(567,000)
Common stock issued for cash, shares	1,620,000
Common stock issued for services	$ 431	214,394			(214,825)
Common stock issued for services, shares	431,500
Common stock issued for services-Gel-Del				32,171		32,171
Inducement dividend from warrant exercise		30,000				30,000
Change in ownership in VIE	$ 5,450	14,330,280		(14,335,730)
Change in ownership in VIE, shares	5,450,000
Net loss			(2,337,338)			(2,337,338)
Balance at Mar. 31, 2018	$ 18,279	47,257,557	(47,748,154)		608,966	136,648
Balance, shares at Mar. 31, 2018	18,279,075
Common stock issued to reduce debt	$ 521	276,910			(181,967)	95,464
Common stock issued to reduce debt, shares	520,749
Proceeds from stock sale						93,893
Stock based compensation granted	$ 200	41,800			(42,000)
Stock based compensation granted, shares	200,000
Common stock issued for cash	$ 370	369,630			(276,107)	93,893
Common stock issued for cash, shares	370,000
Common stock issued for services	$ 334	599,166			(12,300)	587,200
Common stock issued for services, shares	334,723
Common stock returned	$ 479	861,113				861,592
Common stock returned, shares	478,662
Warrants for services		173,184				173,184
Warrant compensation		106,127				106,127
Net loss			(2,099,585)			(2,099,585)
Balance at Jun. 30, 2018	$ 20,183	$ 49,685,487	$ (49,847,739)		$ 96,592	$ (45,477)
Balance, shares at Jun. 30, 2018	20,183,209

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
CASH FLOWS USED IN OPERATING ACTIVITIES:
Net Loss For The Period	$ (2,099,585)	$ (501,031)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Non-cash consulting expense		32,172
Depreciation and amortization	161,119	162,320
Warrants issued for services	173,184
Warrant compensation	106,127
Stock issued to reduce debt	95,464
Stock issued for services	587,200	156,825
Stock compensation adjustment	861,592
Changes in Operating Assets and Liabilities
Increase in inventory	(78,730)
Decrease (increase) in prepaid expense and employee advances	(6,547)	206
Decrease (increase) in advances and receivables	163	(163)
Increase in accounts payable and accrued expense	(49,774)	101,698
Increase of accrued expenses - related party	5,182
Net Cash Used in Operating Activities	(244,605)	(47,973)
CASH FLOWS USED IN INVESTING ACTVITITES
Decrease (Increase) in security deposit	1,999	(8,201)
Purchase of equipment	(23,181)
Increase in patents and trademarks	(32,612)	(5,901)
Net Cash Used in Investing Activities	(53,794)	(14,102)
CASH FLOWS USED IN FINANCING ACTIVITIES
Proceeds from stock sale	93,893	31,500
Common stock subscribed		10,500
Decrease in Note payable and accrued interest	(503)
Net Cash Provided by Financing Activities	93,390	42,000
Net Decrease in Cash	(205,009)	(20,075)
Cash at Beginning of Period	237,335	25,434
Cash at End of Period	32,326	5,359
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash Paid During The Year For: Interest	2,497
Cash Paid During The Year For: Income taxes paid
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Shares issued as payment for accrued salaries		1,209,919
Change in variable interest equity		$ 14,335,730

Summary of Significant Accounti

Summary of Significant Accounting Policies and Organization	3 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Significant Accounting Policies and Organization	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009, and entered it current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at June 30, 2018 and for the three months ended June 30, 2018 and 2017 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three months ended June 30, 2018 are not necessarily indicative of the results to be expected for the year ended March 31, 2019 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2018, included in our annual report on Form 10-K filed with the SEC. The Company is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. The Company’s management development and other operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. The accounting for the acquisition of Gel-Del Technologies, Inc. began with the Security Exchange Agreement on April 10, 2015 which was uncompleted, and as adjusted for completion pursuant to the Agreement and Plan of Merger effective April 10, 2017 (the “Merger”). To complete the Merger, the Company issued 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000 on the date of completion (April 10, 2017). (C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest. (D) Cash and Cash Equivalents The Company considers all highly-liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At June 30, 2018, the Company had $32,326 in cash and no cash equivalents. (E) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At June 30, 2018, cash did not exceed the FDIC uninsured balances. The management believes the Company is not exposed to any significant credit risk on cash. (F) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures. (G) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months. (H) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,448,923 warrants outstanding as of June 30, 2018 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.56/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive. (I) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. Revenues consist of Kush™ product sales to veterinary clinics. (J) Research and Development The Company expenses research and development costs as incurred. (K) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related party, notes payable, notes payable - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2018 and March 31, 2018, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no assets and liabilities measured at fair value on a recurring basis at June 30, 2018 and March 31, 2018. (L) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised. (M) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company adopted the provisions of ASC Topic 740, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards No. 5, Accounting for Contingencies. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (L) Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company expects to recognize ROU assets and related obligations upon adoption of ASU 2016-02. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. The change from revenue recognition according to FASB issued ASC 605 to ASC 606 had no effect on the Company’s financial statements for the years ending March 31, 2017 and March 31, 2018, or the quarters ending June 30, 2017, and June 30, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Related Party Payable

Related Party Payable	3 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Payable	NOTE 2 - RELATED PARTY PAYABLE At June 30, 2018, the company is obligated for an officer note payable and accrued interest in the total amount of $102,776.

Going Concern

Going Concern	3 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3 - GOING CONCERN As reflected in the accompanying condensed consolidated financial statements, the Company had no significant revenue and had a negative equity and recurring material losses. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management intends to raise additional funds either through a private placement or public offering of its equity securities. Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its viability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Common Stock and Warrants

Common Stock and Warrants	3 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Common Stock and Warrants	NOTE 4 - COMMON STOCK AND WARRANTS Common Stock During the three-month period ended June 30, 2018 the Company issued 1,904,134 shares of common stock including: i) 478,662 were issued to the Company’s President, John Lai, to replace shares he placed into escrow in 2017 valued at $861,592; ii) 520,749 shares were to reduce debt valued at $277,431, 485,287 of these shares valued at $181,967 were recorded in our financial statements during fiscal year ended March 31, 2018; iii) 200,000 were issued as compensation to the Company’s CEO, Wesley Hayne, valued at $42,000, these shares were granted and recorded to expense and Additional Paid in Capital during the fiscal year ended March 31, 2018; iv) 370,000 were issued for cash valued at $370,000, 60,000 of which were due to the exercise of warrants at $1.00 per share, 250,000 were from a private offering to one individual in December of 2017 for $250,000, and 60,000 were from a private offering to one individual in September of 2016 for $60,000; v) 334,723 were issued for services valued at $599,500, 324,723 shares valued at $584,500 were issued to the Company’s President, John Lai, to replace shares given up to obtain financing in 2015. Warrants During the three-month period ended June 30, 2018 the Company granted warrants to purchase a total of 250,000 shares of common stock including: i) warrants for 80,000 shares to two advisory board members for service, vested semi-annually over two years, and exercisable over a five-year term at $1.00/share; ii) warrants for 80,000 shares to John Carruth, the Company’s Controller, in consideration of his employment, vested quarterly over two years, and exercisable over a five-year term at $1.00/share; iii) warrants for 30,000 shares to a lawyer for general legal counsel, fully-vested and exercisable over a five-year term at $1.00/share; iv) warrants for 60,000 shares to various information technology service providers for IT services, vested as billed, exercisable over a five-year term. During the three-month period ended June 30, 2018 the Company reduced previous grants of warrants to purchase 100,000 shares of common stock including: i) warrants for 60,000 shares from a service provider due to the termination of a contract; ii) warrants for 40,000 shares from a former advisory board member due to the termination of a contract. During the three-month period ended June 30, 2018 warrants to purchase 187,786 shares of common stock with a strike price of $.50 per share were exercised for $93,893 in cash. A summary of warrant activity for the periods ending March 31, 2018 and June 30, 2018 is as follows: Number of Warrants Weighted-Average Exercise Price Warrants Exercisable Weighted-Average Exercisable Price Outstanding, March 31, 2017 133,250 2.00 133,250 2.00 Granted 3,413,459 .54 Exercised 60,000 1.50 Outstanding, March 31, 2018 3,486,709 .59 2,433,601 .57 Granted 250,000 1.00 Exercised 187,786 .50 Canceled 100,000 1.00 Outstanding, June 30, 2018 3,448,923 .61 2,316,974 .56 At June 30, 2018, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Number of Warrants Weighted-Average Exercise Price .30-.50 2,615,673 .43 2.76 2,120,673 .46 .51-1.00 760,000 1.03 4.66 123,051 1.00 1.01-3.50 73,250 2.82 2.44 73,250 2.82

Merger Agreement with Gel-Del

Merger Agreement with Gel-Del	3 Months Ended
	Jun. 30, 2018
Merger Agreement With Gel-del
Merger Agreement with Gel-Del	NOTE 5 – MERGER AGREEMENT WITH GEL-DEL On November 21, 2014, the respective Boards of Directors and executive officers of our company and of Gel-Del Technologies, Inc., a Minnesota corporation (“Gel-Del”), entered into and agreed to a merger between our company and Gel-Del, subject to approval by our shareholders and the shareholders of Gel-Del. Approval of our shareholders of this initial merger was obtained by us on April 10, 2015 through a Written Consent pursuant to Nevada corporate statutes, and approval of Gel-Del shareholders was obtained through a meeting of its shareholders duly held on March 25, 2015 pursuant to Minnesota corporate statutes. Concurrent with obtaining full shareholder approval, we also appointed the directors of Gel-Del as directors of our company. We then controlled Gel-Del, combined all Gel-Del operations with ours, and became responsible to provide future funding for Gel-Del. Accordingly, we concluded that Gel-Del was a VIE entity for which we were the primary beneficiary and that for accounting purposes, we would consolidate our financial statements with those of Gel-Del. As required by US GAAP accounting, our initial consolidation of this VIE was accounted for similar to a business combination with the assets and liabilities of Gel-Del stated at their fair value. In light of the pending merger, we determined the fair value of Gel-Del based on the agreed consideration of 4,150,000 common shares using the $4.02 per share trading price of our common stock at April 10, 2015. The assets of Gel-Del equaled $295,716 and its liabilities were $2,295,462 for a difference of $1,999,746 that resulted in a total purchase consideration of $18,978,462. We allocated $13,407,693 to goodwill and $5,570,769 to patents and trademarks. We recorded a non-controlling interest of $16,683,000. We were unable to consummate the initial merger agreement with Gel-Del due primarily to a substantial public market decline in the trading value of our common stock. In order to complete our Gel-Del merger, in early 2017 we agreed to provide Gel-Del an additional 31.3% of our common shares than was provided for in the initial merger agreement. Accordingly, pursuant to an Agreement of Merger dated March 20, 2017, our management and Gel-Del management revised the structure and terms of the Gel-Del merger to provide for the issuance of these additional shares to Gel-Del and to effect the transaction through a statutory triangular merger. The revised merger was then completed under Minnesota Statutes whereby Gel-Del and a wholly-owned subsidiary of ours (which was incorporated in Minnesota expressly for this transaction) completed this triangular merger (the “Merger”). Pursuant to the Merger, Gel-Del was the surviving entity and concurrently became our wholly-owned subsidiary, resulting in our obtaining full ownership of Gel-Del. Our primary reason to effect the Merger was to obtain 100% ownership and control of Gel-Del and its patented bioscience technology, including ownership of Gel-Del’s Cosmeta subsidiary. The effective date for the Merger was April 10, 2017 when the Merger was filed officially with the Secretary of State of Minnesota. Pursuant to the Merger, we issued a total of 5,450,000 shares of our common stock pro rata to the pre-merger shareholders of Gel-Del, resulting in each outstanding common share of Gel-Del being converted into 0.788 common share of our company. Gel-Del did not have any outstanding options, warrants, convertible debt, or other rights convertible into equity. The 5,450,000 shares represented approximately 30% of our total post-merger outstanding common shares and were valued at the closing price of our common shares on the effective date of the Merger of $0.40 per share, resulting in total consideration of $2,180,000. Incident to completion of the Merger, we recorded an impairment loss of approximately $14,700,000 including $13,407,693 in goodwill and approximately $1,292,307 in patents and trademarks, in order to account for the decline in our initial valuation of Gel-Del. In accordance with authoritative guidance, the non-controlling interest associated with Gel-Del was reclassified to additional paid-in capital, including the difference between the non-controlling interest and the consideration paid.

Lease and Commitments

Lease and Commitments	3 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Lease and Commitments	NOTE 6 – LEASE AND COMMITMENTS Rent expense for the three months ended June 30, 2018 & June 30, 2017 were $14,607 and $13,693, respectively. In February of 2018 the Company entered into a lease with a 90-day notice clause for 500 square feet of manufacturing and office space in Rochester, MN. The Company entered into an eighty-four month lease for 3,577 square feet of newly constructed office, laboratory and warehouse space located in Edina, Minnesota on May 3, 2017. The base rent is $2,078 per month and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. Future minimum rental commitments are as follows: Year Ended March 31, 2019 $ 18,702 2020 $ 24,936 2021 $ 24,936 2022 $ 24,936 2023 $ 24,936 Thereafter $ 21,770 $ 140,216

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 7 – SUBSEQUENT EVENTS On July 2 nd On August 14 th

Summary of Significant Accoun14

Summary of Significant Accounting Policies and Organization (Policies)	3 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	\ (A) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009, and entered it current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in Minnesota PetVivo becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly owned subsidiary of the Company. The accompanying condensed consolidated financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and note disclosures, which are included in annual financial statements, have been omitted pursuant to these rules and regulations. We believe the disclosures made in these interim unaudited financial statements are adequate to make the information not misleading. Although these interim financial statements at June 30, 2018 and for the three months ended June 30, 2018 and 2017 are unaudited, in the opinion of our management, such statements include all adjustments (consisting of normal recurring entries) necessary to present fairly our financial position, results of operations and cash flows for the periods presented. The results for the three months ended June 30, 2018 are not necessarily indicative of the results to be expected for the year ended March 31, 2019 or for any future period. These unaudited interim financial statements should be read and considered in conjunction with our audited financial statements and the notes thereto for the year ended March 31, 2018, included in our annual report on Form 10-K filed with the SEC. The Company is in the business of distribution of medical devices and biomaterials for the treatment of afflictions and diseases in animals. The Company’s management development and other operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Principles of Consolidation	(B) Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations. All intercompany accounts have been eliminated upon consolidation. The accounting for the acquisition of Gel-Del Technologies, Inc. began with the Security Exchange Agreement on April 10, 2015 which was uncompleted, and as adjusted for completion pursuant to the Agreement and Plan of Merger effective April 10, 2017 (the “Merger”). To complete the Merger, the Company issued 5,450,000 shares valued at market at $0.40 per share, which equaled $2,180,000 on the date of completion (April 10, 2017).
Use of Estimates	(C) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, estimate of fair value of share-based payments and derivative instruments and recorded debt discount, valuation of deferred tax assets and valuation of in-kind contribution of services and interest.
Cash and Cash Equivalents	(D) Cash and Cash Equivalents The Company considers all highly-liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. At June 30, 2018, the Company had $32,326 in cash and no cash equivalents.
Concentration-risk	(E) Concentration-Risk The Company maintains its cash with various financial institutions, which at times may exceed limits insured by the Federal Deposit Insurance Corporation (FDIC). At June 30, 2018, cash did not exceed the FDIC uninsured balances. The management believes the Company is not exposed to any significant credit risk on cash.
Property & Equipment	(F) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after taking into account their respective estimated residual values) over the assets estimated useful life of (3) years for equipment, (5) years for automobile, and (7) years for furniture and fixtures.
Patents and Trademarks	(G) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over a useful life of 60 months.
Loss Per Share	(H) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company has 3,448,923 warrants outstanding as of June 30, 2018 with varying exercise prices ranging from $3.50 to $.30/share. The weighted average exercise price for these warrants is $.56/share. These warrants are excluded from the weighted average number of shares because they are considered anti-dilutive.
Revenue Recognition	(I) Revenue Recognition The Company will recognize revenue on arrangements in accordance with FASB ASC No. 606, “Revenue From Contracts With Customers”. Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. The Company adopted the guidance on April 1, 2018 using the cumulative catch-up transition method. This change in accounting did not have any material effect on the Company’s financial statements. Revenues consist of Kush™ product sales to veterinary clinics.
Research and Development	(J) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(K) Fair Value of Financial Instruments The Company applies the accounting guidance under FASB ASC 820-10, “Fair Value Measurements” The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, accrued expenses – related party, notes payable, notes payable - related party, and convertible notes payable. The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2018 and March 31, 2018, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s notes recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market and (iii) contractual prices. The Company had no assets and liabilities measured at fair value on a recurring basis at June 30, 2018 and March 31, 2018.
Stock-based Compensation - Non-employees	(L) Stock-Based Compensation - Non-Employees Equity Instruments Issued to Parties Other Than Employees for Acquiring Goods or Services The Company accounts for equity instruments issued to parties other than employees for acquiring goods or services under guidance of Sub-topic 505-50 of the FASB Accounting Standards Codification (“Sub-topic 505-50”). Pursuant to ASC Section 505-50-30, all transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date used to determine the fair value of the equity instrument issued is the earlier of the date on which the performance is complete or the date on which it is probable that performance will occur. If the Company is a newly formed corporation or shares of the Company are thinly traded the use of share prices established in the Company’s most recent private placement memorandum (“PPM”), or weekly or monthly price observations would generally be more appropriate than the use of daily price observations as such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. The fair value of share options and similar instruments is estimated on the date of grant using a Black-Scholes option-pricing valuation model. The ranges of assumptions for inputs are as follows: ● Expected term of share options and similar instruments: Pursuant to Paragraph 718-10-50-2(f)(2)(i) of the FASB Accounting Standards Codification the expected term of share options and similar instruments represents the period of time the options and similar instruments are expected to be outstanding taking into consideration of the contractual term of the instruments and holder’s expected exercise behavior into the fair value (or calculated value) of the instruments. The Company uses historical data to estimate holder’s expected exercise behavior. If the Company is a newly formed corporation or shares of the Company are thinly traded the contractual term of the share options and similar instruments is used as the expected term of share options and similar instruments as the Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. ● Expected volatility of the entity’s shares and the method used to estimate it. Pursuant to ASC Paragraph 718-10-50-2(f)(2)(ii) a thinly-traded or nonpublic entity that uses the calculated value method shall disclose the reasons why it is not practicable for the Company to estimate the expected volatility of its share price, the appropriate industry sector index that it has selected, the reasons for selecting that particular index, and how it has calculated historical volatility using that index. The Company uses the average historical volatility of the comparable companies over the expected contractual life of the share options or similar instruments as its expected volatility. If shares of a company are thinly traded the use of weekly or monthly price observations would generally be more appropriate than the use of daily price observations as the volatility calculation using daily observations for such shares could be artificially inflated due to a larger spread between the bid and asked quotes and lack of consistent trading in the market. ● Expected annual rate of quarterly dividends. An entity that uses a method that employs different dividend rates during the contractual term shall disclose the range of expected dividends used and the weighted-average expected dividends. The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the expected term of the share options and similar instruments. ● Risk-free rate(s). An entity that uses a method that employs different risk-free rates shall disclose the range of risk-free rates used. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the expected term of the share options and similar instruments. Pursuant to Paragraphs 505-50-25-8 and 505-50-25-9, an entity may grant fully vested, non-forfeitable equity instruments that are exercisable by the grantee only after a specified period of time if the terms of the agreement provide for earlier exercisability if the grantee achieves specified performance conditions. Any measured cost of the transaction shall be recognized in the same period(s) and in the same manner as if the entity had paid cash for the goods or services or used cash rebates as a sales discount instead of paying with, or using, the equity instruments. A recognized asset, expense, or sales discount shall not be reversed if a share option and similar instrument that the counterparty has the right to exercise expires unexercised.
Income Taxes	(M) Income Taxes The Company accounts for income taxes under Accounting Standards Codification (ASC) Topic 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The Company adopted the provisions of ASC Topic 740, on January 1, 2007. Previously, the Company had accounted for tax contingencies in accordance with Statement of Financial Accounting Standards No. 5, Accounting for Contingencies. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Recent Accounting Pronouncements	(L) Recent Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Topic 842 affects any entity that enters into a lease, with some specified scope exemptions. The guidance in this ASU supersedes Topic 840, Leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (“ROU”) asset representing its right to use the underlying asset for the lease term. For public companies, the amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company expects to recognize ROU assets and related obligations upon adoption of ASU 2016-02. The Company does not expect the adoption on this new standard to have any material effect upon the financial statements. The change from revenue recognition according to FASB issued ASC 605 to ASC 606 had no effect on the Company’s financial statements for the years ending March 31, 2017 and March 31, 2018, or the quarters ending June 30, 2017, and June 30, 2018. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable.

Common Stock and Warrants (Tabl

Common Stock and Warrants (Tables)	3 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Warrant Activity	A summary of warrant activity for the periods ending March 31, 2018 and June 30, 2018 is as follows: Number of Warrants Weighted-Average Exercise Price Warrants Exercisable Weighted-Average Exercisable Price Outstanding, March 31, 2017 133,250 2.00 133,250 2.00 Granted 3,413,459 .54 Exercised 60,000 1.50 Outstanding, March 31, 2018 3,486,709 .59 2,433,601 .57 Granted 250,000 1.00 Exercised 187,786 .50 Canceled 100,000 1.00 Outstanding, June 30, 2018 3,448,923 .61 2,316,974 .56
Schedule of Range of Warrant Prices	At June 30, 2018, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (Years) Number of Warrants Weighted-Average Exercise Price .30-.50 2,615,673 .43 2.76 2,120,673 .46 .51-1.00 760,000 1.03 4.66 123,051 1.00 1.01-3.50 73,250 2.82 2.44 73,250 2.82

Lease and Commitments (Tables)

Lease and Commitments (Tables)	3 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Commitments	Future minimum rental commitments are as follows: Year Ended March 31, 2019 $ 18,702 2020 $ 24,936 2021 $ 24,936 2022 $ 24,936 2023 $ 24,936 Thereafter $ 21,770 $ 140,216

Summary of Significant Accoun17

Summary of Significant Accounting Policies and Organization (Details Narrative) - USD ($)	Apr. 10, 2017	Jun. 30, 2018
Cash		$ 32,326
Cash equivalents
Warrants outstanding		3,448,923
Weighted average exercise price of warrants price per share		$ 0.56
Income tax likelihood percentage		greater than 50 percent
Maximum [Member]
Weighted average exercise price of warrants price per share		$ 3.50
Minimum [Member]
Weighted average exercise price of warrants price per share		$ 0.30
Patents And Trademarks [Member]
Estimated useful life of intangible asset		60 months
Equipment [Member]
Estimated useful life of assets		3 years
Automobiles [Member]
Estimated useful life of assets		5 years
Furniture and Fixtures [Member]
Estimated useful life of assets		7 years
Gel-Del Technologies, Inc [Member]
Number of shares issued during period	5,450,000
Market price per share	$ 0.40
Issued shares equaled value	$ 2,180,000

Related Party Payable (Details

Related Party Payable (Details Narrative) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Related Party Transactions [Abstract]
Note payable and accrued interest	$ 102,776	$ 103,279

Common Stock and Warrants (Deta

Common Stock and Warrants (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
	Dec. 31, 2017	Sep. 30, 2016	Jun. 30, 2018	Mar. 31, 2018
Value of shares issued during period			$ 93,893
Common stock issued to reduce debt			95,464
Stock based compensation granted				863,871
Exercise price per share of warrants			$ 0.56
Number of shares issued during period for services			$ 587,200
Common Stock [Member]
Number of shares issued during period, shares			1,904,134
Common stock issued to reduce debt, shares			520,749	485,287
Common stock issued to reduce debt			$ 277,431	$ 181,967
Common stock issued for cash, shares			370,000
Common stock issued for cash			$ 370,000
Number of warrants exercise or issued			60,000
Exercise price per share of warrants			$ 1
Number of shares issued during period for services, shares			334,723
Number of shares issued during period for services			$ 599,500
Common Stock [Member] | John Lai [Member]
Number of shares issued during period, shares			478,662
Value of shares issued during period			$ 861,592
Number of shares issued during period for services, shares			324,723
Number of shares issued during period for services			$ 584,500
Common Stock [Member] | Wesley Hayne [Member]
Stock based compensation granted, shares				200,000
Stock based compensation granted				$ 42,000
Common Stock [Member] | One Individual [Member]
Number of shares issued during period, shares	250,000	60,000
Value of shares issued during period	$ 250,000	$ 60,000
Warrant [Member]
Number of warrants exercise or issued			250,000
Warrant [Member] | Two Advisory Board Members [Member]
Number of warrants exercise or issued			80,000
Exercise price per share of warrants			$ 1
Warrant vested, description			Vested semi-annually over two years
Warrant term			5 years
Warrant [Member] | John Carruth [Member]
Number of warrants exercise or issued			80,000
Exercise price per share of warrants			$ 1
Warrant vested, description			Vested quarterly over two years
Warrant term			5 years
Warrant [Member] | Lawyer [Member]
Number of warrants exercise or issued			30,000
Exercise price per share of warrants			$ 1
Warrant term			5 years
Warrant [Member] | Information Technology Service [Member]
Number of warrants exercise or issued			60,000
Warrant term			5 years
Warrant One [Member]
Number of warrants exercise or issued			100,000
Warrant One [Member] | Service Provider [Member]
Number of warrants exercise or issued			60,000
Warrant One [Member] | Former Advisory [Member]
Number of warrants exercise or issued			40,000
Warrant Two [Member]
Number of warrants exercise or issued			187,786
Exercise price per share of warrants			$ 0.50
Warrant exercise value			$ 93,893

Common Stock and Warrants - Sch

Common Stock and Warrants - Schedule of Warrant Activity (Details) - Warrant [Member] - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Number of Warrants, Outstaning, Beinning Balance	3,486,709	133,250
Number of Warrants, Granted	250,000	3,413,459
Number of Warrants, Exercised	187,786	60,000
Number of Warrants, Cancelled	100,000
Number of Warrants, Outstaning, Ending Balance	3,448,923	3,486,709
Weighted-Average Exercise Price, Outstaning, Beinning Balance	$ 0.59	$ 2
Weighted-Average Exercise Price, Granted	1	.54
Weighted-Average Exercise Price, Exercised	0.50	1.50
Weighted-Average Exercise Price, Cancelled	1
Weighted-Average Exercise Price, Outstaning, Ending Balance	$ 0.61	$ 0.59
Warrants Exercisable, Outstaning, Beinning Balance	2,433,601	133,250
Warrants Exercisable, Granted
Warrants Exercisable, Exercised
Warrants Exercisable, Cancelled
Warrants Exercisable, Outstaning, Ending Balance	2,316,974	2,433,601
Weighted-Average Exercisable Price, Outstaning, Beinning Balance	$ 0.57	$ 2
Weighted-Average Exercisable Price, Granted
Weighted-Average Exercisable Price, Exercised
Weighted-Average Exercisable Price, Cancelled
Weighted-Average Exercisable Price, Outstaning, Ending Balance	$ 0.56	$ 0.57

Common Stock and Warrants - S21

Common Stock and Warrants - Schedule of Range of Warrant Prices (Details) - Warrant [Member]	3 Months Ended
	Jun. 30, 2018$ / sharesshares
Range One [Member]
Range of Warrant Exercise Price, Outstanding	$ .30
Range of Warrant Exercise Price, Outstanding	$ .50
Number of Warrants, Outstanding | shares	2,615,673
Weighted-Average Exercise Price, outstanding	$ 0.43
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 9 months 3 days
Number of Warrants, Exercisable | shares	2,120,673
Weighted-Average Exercise Price, Exercisable	$ 0.46
Range Two [Member]
Range of Warrant Exercise Price, Outstanding	0.51
Range of Warrant Exercise Price, Outstanding	$ 1
Number of Warrants, Outstanding | shares	760,000
Weighted-Average Exercise Price, outstanding	$ 1.03
Weighted-Average Remaining Contractual Life (Years), Outstanding	4 years 7 months 28 days
Number of Warrants, Exercisable | shares	123,051
Weighted-Average Exercise Price, Exercisable	$ 1
Range Three [Member]
Range of Warrant Exercise Price, Outstanding	1.01
Range of Warrant Exercise Price, Outstanding	$ 3.50
Number of Warrants, Outstanding | shares	73,250
Weighted-Average Exercise Price, outstanding	$ 2.82
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 5 months 9 days
Number of Warrants, Exercisable | shares	73,250
Weighted-Average Exercise Price, Exercisable	$ 2.82

Merger Agreement with Gel-Del (

Merger Agreement with Gel-Del (Details Narrative) - USD ($)	Apr. 10, 2015	Jun. 30, 2018
Common shares aggregate consideration	Determined the fair value of Gel-Del based on the agreed consideration of 4,150,000 common shares using the $4.02 per share trading price
Fair value determined based on agreed consideration of common shares	4,150,000
Share price	$ 4.02
Assets value		$ 295,716
Liabilities value		2,295,462
Assets acquired and liabilities assumed		1,999,746
Total purchase consideration		18,978,462
Goodwill		13,407,693
Patents and trademarks		5,570,769
Non-controlling interest		$ 16,683,000
Ownership percentage		100.00%
Merger agreement converted, description
Effective Date of Merger [Member]
Total purchase consideration		$ 2,180,000
Acquisition of common stock outstanding, percentage		30.00%
Share issued price per share		$ 0.40
Completion of Merger [Member]
Goodwill		$ 13,407,693
Patents and trademarks		1,292,307
Impairment loss		$ 14,700,000
Initial Merger Agreement [Member]
Ownership percentage		31.30%
Number of common stock shares issued		5,450,000
Merger agreement converted, description		Each outstandng common share of Gel-Del being converted into 0.788 common share of our company.

Lease and Commitments (Details

Lease and Commitments (Details Narrative)	3 Months Ended
	Jun. 30, 2018USD ($)	Jun. 30, 2017USD ($)	Feb. 28, 2018ft²	May 03, 2017ft²
Rent expense | $	$ 14,607	$ 13,693
90 Days of Lease [Member]
Area of land | ft²			500
Eighty-Four Month of Lease [Member]
Rent expense | $	$ 2,078
Area of land | ft²				3,577

Lease and Commitments - Schedul

Lease and Commitments - Schedule of Future Minimum Rental Commitments (Details)	Jun. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 18,702
2,020	24,936
2,021	24,936
2,022	24,936
2,023	24,936
There after	21,770
Total	$ 140,216

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jul. 02, 2018ft²
Subsequent Event [Member]
Area of land	1,000